ART Has Changed the Cancers Associated with HIV

New York—Antiretroviral therapy transformed infection with human immunodeficiency virus (HIV) from a death sentence to a chronic condition, along the way changing virtually everything about the disease, including its association with cancer. For years, specific...

Agent Orange Linked to Overall Head/Neck Cancers

PORTLAND, OR — Agent Orange exposure might have had more effect than previously assumed on development of head and neck cancers, according to a recent study. A report in the Oral Oncology journal described how self-reported Agent Orange exposure was linked with...

HIV Patients Had Lower PC Incidence in VA Study

NEW YORK—Non-AIDS defining cancers are increasingly important contributors to health outcomes for aging persons with HIV (PWH), according to a recent conference presentation which also pointed out that, although prostate cancer is prevalent in aging men, the impact of...

VA Study Finds No Link Between ADT, Dementia

LA JOLLA, CA—Research has been conflicting on whether androgen deprivation therapy is related to dementia. A research letter in JAMA Oncology pointed out that two studies reported a strong statistically significant association between ADT and both dementia and...

Agent Orange Exposure Not Associated With Worse PC Outcomes

MADISON, WI—How does a history of Agent Orange exposure affect prostate cancer survival in VA patients receiving androgen deprivation therapy for advanced prostate cancer? That was the question addressed in a Journal of Urology study.1 University of Wisconsin School...

Oral Cancer Therapies Create Critical Demand for Pharmacists

CHICAGO—The pace of U.S. Food and Drug Administration approval of oral anticancer medications has rapidly increased, from less than one a year at the turn of the century to 10 in 2018. While patients generally prefer taking oncolytics by mouth at home to intravenous...

Cancer Trials Boom in VA’s New England Region

Cancer Trials Boom in VA’s New England Region

The number of clinical trials open to veterans with cancer in the New England region (VISN 1) grows every week, leading a return to the prominence the VA had in trial programs in decades past and offering veterans access to the “gold standard” of treatment in oncology.

CE Credits